Pulsenmore (NASDAQ, TASE: PLSM) is the world’s first at-home diagnostic ultrasound and telehealth platform for pregnancy well check, bringing imaging into the home and connecting patients with care teams remotely. Positioned at the intersection of telehealth and femtech, Pulsenmore integrates ultrasound imaging with virtual prenatal care to support earlier insights, improved continuity of care, and greater access. Clinically validated and supported by large-scale commercial adoption, the platform has enabled more than 220,000 home self-scans worldwide.

Pulsenmore is the only FDA-Authorized Home Ultrasound, approved for commercial use in the U.S., Europe, the UK, Switzerland, Australia, Brazil, Colombia, and Israel.